Wilmington Savings Fund Society FSB Sells 886 Shares of Edwards Lifesciences Co. (NYSE:EW)

Wilmington Savings Fund Society FSB trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,220 shares of the medical research company’s stock after selling 886 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Edwards Lifesciences were worth $609,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $30,000. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC raised its position in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $46,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,000 shares of company stock worth $547,430 over the last 90 days. 1.29% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently commented on EW shares. Royal Bank of Canada increased their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Robert W. Baird dropped their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Piper Sandler reduced their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.19.

Edwards Lifesciences Stock Up 1.0 %

Shares of NYSE EW opened at $71.05 on Tuesday. The firm has a fifty day simple moving average of $72.45 and a two-hundred day simple moving average of $69.18. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $41.91 billion, a PE ratio of 10.25, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.